Related Experiment Video
Updated: May 7, 2026
12:18
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
Prediction of conversion from mild cognitive impairment to Alzheimer disease based on bayesian data mining with
1Department of Radiology, University of Pennsylvania; Philadelphia, PA, USA - rong.chen@uphs.upenn.edu.
The Neuroradiology Journal
|September 14, 2013
Summary
A new Bayesian method, BOPEL, accurately predicts Alzheimer's disease progression in individuals with mild cognitive impairment using brain imaging data. This approach overcomes limitations of previous models, offering improved prediction accuracy for early diagnosis and intervention.
Area of Science:
- Neuroscience
- Medical Imaging
- Computational Biology
Background:
- Predicting Alzheimer's disease (AD) progression is crucial for research and clinical practice.
- Prior predictive models faced challenges like undersampling and limited to linear associations.
- Mild cognitive impairment (MCI) is a prodromal stage of AD, making its prediction vital.
Purpose of the Study:
- To introduce a novel Bayesian data-mining method, Bayesian Outcome Prediction with Ensemble Learning (BOPEL).
- To address limitations of previous predictive models, specifically undersampling and linear association restrictions.
- To predict the conversion of individuals with MCI to AD using neuroimaging data.
Main Methods:
- Developed BOPEL, a Bayesian-network approach with boosting for detecting nonlinear multivariate associations.
- Incorporated resampling-based feature selection to mitigate overfitting from undersampling.
- Utilized structural MRI and MR spectroscopy data from 26 amnestic MCI subjects (8 converters, 18 non-converters).
Main Results:
- BOPEL accurately differentiated MCI converters from non-converters.
- Key predictors included baseline brain volumes of specific regions: left hippocampus, right superior temporal sulcus, right entorhinal cortex, left lingual gyrus, and left middle frontal gyrus.
- Achieved prediction accuracy of 0.81 (sensitivity 0.63, specificity 0.89), validated with an independent dataset (0.75 accuracy).
Conclusions:
- BOPEL offers a robust method for predicting Alzheimer's disease conversion in MCI patients.
- The model's ability to detect nonlinear associations and handle undersampling enhances predictive power.
- High predictive accuracy suggests clinical utility for early identification and intervention strategies in Alzheimer's disease.
Related Concept Videos
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...